Single-Arm Combined Phase I/II Study Evaluating Limb Cryocompression to Prevent Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Taxane-Based Chemotherapy
JCO Oncology Advances · 2026-10 · 3 (4)
DOI: 10.1200/oa-26-00104 ↗Abstract
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity of taxane-based chemotherapy with no established preventive strategy. We evaluated the safety, tolerability, and efficacy of a novel limb cryocompression device in reducing CIPN. Methods In this prospective single-arm phase I/II study conducted at three sites in Singapore, patients with cancer scheduled for taxane-based chemotherapy received limb cryocompression (11°C; cyclic compression 5-15 mm Hg), starting 30 minutes before, during, and 30 minutes after taxane infusion. Primary end points included safety, tolerability, and clinically significant CIPN. CIPN was assessed by physician-graded Common Terminology Criteria for Adverse Events (CTCAE) and the patient-reported European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN 20-item scale (EORTC QLQ-CIPN20). A ≥3-point increase in the EORTC QLQ-CIPN20 sensory subscale defined clinically significant patient-reported CIPN. Taxane dose modifications attributable to CIPN were recorded. Results A total of 150 patients were enrolled (median age 52 years; 96.6% female; 89.0% breast cancer). Taxane regimens included paclitaxel (71.2%), docetaxel (28.1%), and nab-paclitaxel (0.68%); 44.5% received concurrent scalp cooling. A total of 146 patients were evaluable as four patients withdrew before commencing cryocompression. Tolerability was 84.2%; 123 patients completed all cryocompression cycles without premature termination. Fifteen patients (10.3%) withdrew because of cold intolerance. At treatment completion, 22.8% had CTCAE G1 CIPN and 1.6% had G2 CIPN; none developed G3/4 CIPN. Clinically significant patient-reported sensory CIPN occurred in 13.9% at 12 weeks and 13.1% at 24 weeks, and 5.7% required taxane dose modification because of CIPN. Conclusion Limb cryocompression is safe, well-tolerated, and associated with low rates of clinically significant CIPN in patients receiving taxane-based chemotherapy. A multicenter randomized controlled trial is ongoing to validate these findings (SWOG S2205 ICE COMPRESS; ClinicalTrials.gov identifier: NCT05642611 ).
EUVIMED